The Combination of Buspirone and Bupropion in the Treatment of Depression

@article{Fava2007TheCO,
  title={The Combination of Buspirone and Bupropion in the Treatment of Depression},
  author={Maurizio Fava},
  journal={Psychotherapy and Psychosomatics},
  year={2007},
  volume={76},
  pages={311 - 312}
}
  • M. Fava
  • Published 1 August 2007
  • Psychology, Medicine
  • Psychotherapy and Psychosomatics
Case Report A Caucasian woman in her late forties with a history of recurrent episodes of MDD presented with a recurrence of her MDD in the context of her having been off antidepressant medications. Her previous episodes had responded well to the combination of SSRIs (e.g. paroxetine 20 mg q.d.) and bupropion 150 mg q.d. sustained release (SR). Because of concerns about possible side effects (e.g. weight gain) related to SSRI treatment, the patient was started on bupropion 150 mg SR and… 
5 Citations

Asociación de bupropión mirtazapina en depresión resistente: Un estudio observacional.

The combination of bupropion and mirtazapina might be an effective option regarding clinical, pharmacokinetic and pharmacodynamic actions, however, further studies with larger samples in long time are required to demonstrate the clinical use of this therapeutic option.

Therapeutic Options for Treatment-Resistant Depression

Despite an increasing variety of choices for the treatment of TRD, this condition remains universally undefined and represents an area of unmet medical need.

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

  • A. Nierenberg
  • Psychology, Medicine
    Psychotherapy and Psychosomatics
  • 2009
Factors identified as the most important in determining remission from depression are identified.

Patient Management Exercise

Questions are presented at “consideration points” that follow a section that gives information about the case. One or more choices may be correct for each question; make your choices on the basis of

References

SHOWING 1-10 OF 12 REFERENCES

Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.

It is suggested that the effect of buspirone on sexual dysfunction is a result of a reversal of SSRI-induced sexual side effects rather than of an antidepressant effect of the drug.

Medication augmentation after the failure of SSRIs for depression.

Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events.

A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.

Bupropion SR, as an effective antidote to SSRI-induced sexual dysfunction, produced an increase in desire to engage in sexual activity and frequency of engaging inSexual activity compared with placebo.

Tolerability issues during long-term treatment with antidepressants.

  • P. CassanoM. Fava
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2004
Selective serotonin reuptake inhibitors and atypical antidepressants show a relatively favorable short-term as well as long-term tolerability compared with older drugs (e.g., tricyclics and monoamine oxidase inhibitors).

Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice

This paper will review the pertinent studies and propose a novel approach to improve practice involving the use of augmentation or combination strategies at the outset of initial treatment to primarily enhance the chances of remission through synergy and/or a broader spectrum of action.

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.

Serotonergic anxiolytics and treatment of depression.

Clinical findings are consistent with preclinical pharmacology suggesting that 5-HT1A partial agonists may possess intrinsic antidepressant activity and support antidepressant efficacy in addition to anxiolysis.

Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test

Low dose buspirone enhanced the activity of subactive doses of SSRIs in the mouse forced swimming test, probably via an action at 5-HT1A receptors and attenuated all SSRI-induced anti-immobility effects.